Bristol-Myers Squibb’s acquisition of Celgene wasn’t the only big news in January. Read this brief for a comprehensive review of announcements from diagnostic, device and biopharma companies. Gain insights into both business and clinical developments, and get a peek into the in vitro diagnostics, medical devices and pharmaceuticals pipelines.
Author: Beth Detuzzi
Published: 13 February 2019
Number of pages:17
January saw a series of deal announcements from diagnostic, device and biopharma companies. Bristol-Myers Squibb’s acquisition of Celgene Corp. for $74 billion is easily the best known, given that it’s the fourth-largest biopharma acquisition ever. It was far from the only important deal, however. Review this comprehensive list of deal-making activity to learn who’s acquiring, partnering with or financing whom. Gain insights into both business and clinical developments, and get a peek into the in vitro diagnostics, medical devices and pharmaceuticals pipelines. Find out which companies have settled patent litigation. Discover which two companies have inked a partnership to create gene therapies with applications for Alzheimer’s and Parkinson’s.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.